LUPIN

September 30, 2019

The BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is in continuation to our letter dated August 22, 2019, regarding Definitive Agreements entered into by Kyowa Pharmaceutical Industry Co., Ltd. (Kyowa), Japan, a subsidiary of the Company for the sale of Injectables business and related assets of Kyowa CritiCare Co., Ltd. (KCC), Japan, a subsidiary of Kyowa, to the Neopharma Group.

We wish to inform you that the customary closing conditions for the said transaction were completed today i.e. Monday, September 30, 2019. Consequently, KCC has ceased to be a subsidiary of the Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

ACS 11973

R. V. SATAM
COMPANY SECRETARY

LUPIN LIMITED MUMBAI INDIA